Effective treatment of peritoneal myeloid sarcoma with decitabine and venetoclax: A case report

IF 0.9 Q4 HEMATOLOGY

Leukemia Research Reports Pub Date : 2025-01-01 DOI:10.1016/j.lrr.2025.100534

Kavya Sudireddy , Minorvi Amin , Rafy Odeh , Patrick Svrcek , Salwa Khedr , Lloyd Hutchinson , Shyam A. Patel , Jan Cerny , Laurie Pearson

{"title":"Effective treatment of peritoneal myeloid sarcoma with decitabine and venetoclax: A case report","authors":"Kavya Sudireddy , Minorvi Amin , Rafy Odeh , Patrick Svrcek , Salwa Khedr , Lloyd Hutchinson , Shyam A. Patel , Jan Cerny , Laurie Pearson","doi":"10.1016/j.lrr.2025.100534","DOIUrl":null,"url":null,"abstract":"<div><div>Myeloid sarcomas (MS) are rare extramedullary manifestations of myeloid progenitor cells occurring with or without acute myeloid leukemia. Peritoneal MS is exceptionally uncommon, with no established treatment guidelines, but treatment has historically consisted of cytotoxic chemotherapy. We present the case of a 78-year-old female with 60% CD34+, HLA-DR+, and CD33+ myeloblasts in ascitic fluid, while bone marrow biopsy demonstrated only molecular evidence of the leukemic clone with <em>FLT3-ITD, ASXL1</em>, and <em>TET2</em> mutations. Findings were consistent with primary peritoneal myeloid sarcoma. Due to chemotherapy ineligibility, the patient was treated with decitabine and venetoclax. After nine cycles, she demonstrated a complete radiographic response. To our knowledge, this is the first case report of a patient with primary peritoneal MS treated with a combination of a hypomethylating agent and venetoclax.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100534"},"PeriodicalIF":0.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213048925000366","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Myeloid sarcomas (MS) are rare extramedullary manifestations of myeloid progenitor cells occurring with or without acute myeloid leukemia. Peritoneal MS is exceptionally uncommon, with no established treatment guidelines, but treatment has historically consisted of cytotoxic chemotherapy. We present the case of a 78-year-old female with 60% CD34+, HLA-DR+, and CD33+ myeloblasts in ascitic fluid, while bone marrow biopsy demonstrated only molecular evidence of the leukemic clone with FLT3-ITD, ASXL1, and TET2 mutations. Findings were consistent with primary peritoneal myeloid sarcoma. Due to chemotherapy ineligibility, the patient was treated with decitabine and venetoclax. After nine cycles, she demonstrated a complete radiographic response. To our knowledge, this is the first case report of a patient with primary peritoneal MS treated with a combination of a hypomethylating agent and venetoclax.

查看原文本刊更多论文

地西他滨联合维妥乐治疗腹膜髓系肉瘤1例

髓系肉瘤（MS）是罕见的髓系祖细胞髓外表现，伴或不伴急性髓系白血病发生。腹膜性多发性硬化症非常罕见，没有既定的治疗指南，但治疗历史上包括细胞毒性化疗。我们报告了一例78岁的女性患者，腹水中有60%的CD34+、HLA-DR+和CD33+的髓母细胞，而骨髓活检仅显示了带有FLT3-ITD、ASXL1和TET2突变的白血病克隆的分子证据。结果与原发性腹膜髓系肉瘤一致。由于不适合化疗，患者接受地西他滨和维妥乐治疗。9个周期后，她表现出完全的x线片反应。据我们所知，这是第一例用低甲基化药物和venetoclax联合治疗原发性腹膜MS的病例报告。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊